If the first half of 2026 had a thesis, it was validation at scale. A White House executive order directed the FDA to prioritize psychedelic review; Compass Pathways won rolling NDA review and a Commissioner's National Priority Voucher; Definium Therapeutics (the former MindMed) reported the first-ever positive Phase 3 result for a single-dose LSD compound and raised roughly $700 million the next day; and the FDA finalized its psychedelic clinical-trial guidance. The exclamation point came in mid-July, when Eli Lilly agreed to acquire AtaiBeckley for up to $3.8 billion — the largest Big Pharma entry into the space to date.
This mid-year report reviews the regulatory sea change, the pivotal readouts, and the dealmaking that defined the first half of 2026.
Index Performance
The Psychedelic Invest Index (GPI) gained +7.4% across the second quarter of 2026, moving from 224.4 on 2026-03-31 to 241.1 on 2026-06-30. It ranged from an intraperiod low of 215.0 (2026-06-10) to a high of 242.2 (2026-06-29). Track the live index and its constituents on our Stock Index page.
Clinical & Pipeline Milestones
The engine of the sector remains its clinical readouts. Here are the trial results, regulatory designations, and pipeline milestones that moved the needle this period.
Psyence Biomedical Ltd. (PBM). Psyence Biomedical said it expanded its Australian clinical trial network from three to five sites, adding Ramsay Health Care and NeuroCentrix. The sites support an ongoing Phase 2b trial run by Southern Star Research testing nature-derived psilocybin (NPX-5) for adjustment disorder in cancer patients in palliative care. The company said the added capacity should accelerate patient enrollment and broaden the study's geographic reach.
Compass Pathways plc (CMPS). Compass Pathways invited U.S. organizations to apply, from April 14 to May 14, for grants to develop healthcare-provider training for delivering COMP360 psilocybin therapy if approved. The company expects to fund up to three organizations to build foundational psychedelic and COMP360-specific training modules. The move is part of Compass's commercial readiness effort ahead of a targeted end-of-2026 launch preparation for treatment-resistant depression.
Definium Therapeutics, Inc. (DFTX). Definium Therapeutics (the former MindMed) outlined a cluster of near-term catalysts for its DT120 (MM120, an LSD-based ODT) program, teasing three pivotal Phase 3 topline readouts. The company pointed to the Emerge study in major depressive disorder in late Q2 2026, followed by the Voyage and Panorama studies in generalized anxiety disorder in Q3 2026. The timeline positions Definium as one of the busiest late-stage psychedelic pipelines heading into mid-2026.
Helus Pharma (formerly Cybin) (HELP). Helus Pharma (the rebranded Cybin) said Michael Cola stepped down as CEO, effective immediately, at the board's request, with co-founder and Executive Chairman Eric So resuming the interim CEO role while a search proceeds. The leadership change came as the company advances its late-stage psychedelic pipeline, including an anticipated Q4 topline readout from the APPROACH Phase 3 trial of HLP003 (formerly CYB003) in depression. The abrupt transition injected management uncertainty at a pivotal moment for the company.
Definium Therapeutics, Inc. (DFTX). At an Investor and Analyst Day in New York, Definium Therapeutics detailed its DT120 (MM120) clinical and commercial strategy, reiterating three anticipated Phase 3 readouts across MDD and GAD in 2026. The company also announced a program expansion with a planned Phase 3 Haven study in PTSD, enrolling roughly 200 patients randomized 1:1 to DT120 100 µg or placebo. The event underscored Definium's ambition to broaden LSD-based therapy across multiple psychiatric indications.
Psyence Biomedical Ltd. (PBM). Psyence Biomedical said the first patient was dosed in its Phase 2b trial evaluating NPX-5, a 25 mg nature-derived psilocybin product, for adjustment disorder in cancer patients in palliative care. The milestone follows the company's recent expansion of its Australian site network. The dosing marks tangible clinical progress for one of the smaller Nasdaq-listed psychedelic developers amid heightened sector attention.
Compass Pathways plc (CMPS). Compass Pathways said the FDA granted its request for rolling review of the COMP360 psilocybin NDA and selected the program for the Commissioner's National Priority Voucher (CNPV) program in treatment-resistant depression. The voucher promises enhanced FDA communication and a compressed one-to-two-month review after filing. Compass is targeting a rolling NDA submission in Q4 2026, and the designation materially raises the odds of an earlier approval decision.
Source: ir.compasspathways.com
Silo Pharma, Inc. (SILO). Silo Pharma issued a statement welcoming a wave of coordinated U.S. federal actions accelerating psychedelic research, including ARPA-H EVIDENT awards, the FDA's issuance of three National Priority Vouchers and an IND clearance for DemeRx NB. The company highlighted its intranasal PTSD candidate SPC-15 as positioned to benefit from renewed federal focus following the April 18 executive order. Silo framed the policy shift as supportive of its preclinical-to-clinical development plans.
Lykos Therapeutics. The FDA published the previously confidential complete response letter it issued to Lykos Therapeutics in 2024 for MDMA-assisted therapy in PTSD, part of a release of 89 unpublished CRLs under a new transparency policy. The letter detailed concerns including high rates of prior MDMA use among trial participants and screening issues, and it reiterated the agency's request for an additional Phase 3 study. The disclosure sharpened public understanding of the regulatory bar facing MDMA and the broader psychedelic field.
Compass Pathways plc (CMPS). Compass Pathways announced it would report first-quarter 2026 financial results and business highlights on May 13, 2026. The scheduling notice came as investors awaited an update on the company's rolling NDA progress and cash position following its priority-voucher designation. It set up one of the more closely watched psychedelic earnings prints of the quarter.
Reunion Neuroscience. Reunion Neuroscience said it will present full data from its RECONNECT Phase 2 trial of luvesilocin (RE104) in moderate-to-severe postpartum depression at the ASCP and APA annual meetings. The trial met its primary endpoint with a statistically significant MADRS reduction at Day 7, and the FDA granted the candidate Breakthrough Therapy designation in February 2026. Reunion said it expects a single successful Phase 3 trial could complete the data package to support registration in postpartum depression.
Clearmind Medicine Inc. (CMND). Clearmind Medicine said two more patients were dosed in the fourth cohort of its FDA-cleared Phase 1/2a trial of CMND-100 (MEAI) for moderate-to-severe alcohol use disorder, bringing the total treated to 20 across all cohorts. The fourth cohort uses a higher 160 mg dose following a positive safety-monitoring-board recommendation, and the newest patients were treated at Hadassah Medical Center in Jerusalem. The update marks steady enrollment progress for the microcap's lead non-hallucinogenic program.
GH Research PLC (GHRS). GH Research said it would present new Phase 2b data on its inhaled 5-MeO-DMT candidate GH001 for treatment-resistant depression at the American Society of Clinical Psychopharmacology (ASCP) annual meeting in Miami. The presentations cover multiple posters from the GH001-TRD-201 study, including efficacy by prior antidepressant failure and effects on anhedonia. The disclosure keeps investor attention on GH001 as the company advances toward a global Phase 3 program in 2026.
Optimi Health Corp. (OPTH). Optimi Health highlighted final recommendations from Australia's Therapeutic Goods Administration that broaden the Authorized Prescriber scheme for psilocybin (for treatment-resistant depression) and MDMA (for PTSD), widening therapist eligibility and accepted treatment settings. Optimi supplies both products into Australia from its GMP facility in Canada. The expansion supports demand for the company's finished psychedelic drug products in the world's leading regulated prescription market, where coverage now spans private insurers and public schemes such as the DVA and NDIS.
Bright Minds Biosciences Inc. (DRUG). Bright Minds Biosciences presented at the Jefferies Global Healthcare Conference, giving management a platform to update investors on its selective serotonin (5-HT2C) agonist pipeline targeting epilepsy and neuropsychiatric disorders. Conference visibility is meaningful for the small-cap developer, which has drawn heightened sell-side attention in 2026. The appearance is part of ongoing investor-outreach efforts around its lead clinical programs.
Optimi Health Corp. (OPTH). Optimi Health announced it had secured naturally derived ibogaine, in both hydrochloride and freebase forms, from two sources, with development of a finished drug product expected to begin in summer at its GMP facility in British Columbia. The move positions Optimi to supply ibogaine as U.S. federal and Texas-led interest in ibogaine research grows. It extends the company's portfolio beyond psilocybin and MDMA into one of 2026's most closely watched psychedelic compounds.
Reunion Neuroscience Inc.. Reunion Neuroscience named Sahil V. Kirpekar, M.D., as President and CEO and a board member, succeeding Greg Mayes. Kirpekar previously served as Chief Business Officer at atai Life Sciences (now AtaiBeckley), where he helped lead the acquisition of Beckley Psytech. He takes over as the privately held company advances luvesilocin (RE104), a short-duration psilocin-like prodrug that holds FDA Breakthrough Therapy Designation for postpartum depression, with Phase 2 trials underway in adjustment disorder and generalized anxiety disorder.
Definium Therapeutics, Inc. (formerly MindMed) (DFTX). Definium Therapeutics, the rebranded MindMed, reported positive topline results from its pivotal Phase 3 Emerge study of DT120 (formerly MM120, an LSD orally disintegrating tablet) in major depressive disorder. A single 100 microgram dose delivered an 8.1-point placebo-adjusted MADRS improvement at Week 6 (p<0.0001) and a 7.3-point advantage at Week 12, with no serious adverse events or suicidality signal. The readout is the first positive randomized Phase 3 result for a single-dose lysergide compound in a major psychiatric indication, materially de-risking the company's lead program.
Cybin Inc. (d/b/a Helus Pharma) (HELP). Cybin, operating as Helus Pharma, released fiscal-year 2026 results and a business update, reporting that enrollment in its pivotal Phase 3 APPROACH study of HLP003 for adjunctive major depressive disorder had passed 88%, keeping a topline readout on track for Q4 2026. Phase 2 data previously showed roughly a 23-point MADRS improvement at 12 months after two doses. The update reinforces the company's positioning as a late-stage psychedelics developer following its 2026 Nasdaq uplisting and rebrand.
AtaiBeckley Inc. (ATAI). AtaiBeckley announced the last patient was dosed in Elumina, its Phase 2b trial of VLS-01, an oral transmucosal DMT film, in adults with treatment-resistant depression, with topline data expected in Q4 2026. Pending a supportive readout, the company plans to advance VLS-01 into a Phase 3 program in major depressive disorder. The milestone progresses one of AtaiBeckley's wholly owned pipeline assets alongside its lead BPL-003 program.
Compass Pathways plc (CMPS). Compass Pathways released 26-week (Part B) results from COMP006, its second pivotal Phase 3 trial of COMP360 synthetic psilocybin in treatment-resistant depression. About 39% of patients in the 25 mg arm achieved a clinically meaningful MADRS reduction by Week 6 and maintained a durable response through Week 26, while nearly 30% of Week 6 responders went into remission after retreatment. The company said its rolling FDA NDA submission is underway with final submission on track for Q4 2026 and a potential launch in the first half of 2027, subject to approval and DEA rescheduling.
Policy, Regulation & Access
Psychedelic policy accelerated on multiple fronts — federal, state, and international. These developments shape the demand-side runway for every developer we track.
State of Texas (policy). Lt. Governor Dan Patrick and House Speaker Dustin Burrows said Texas will deploy $50 million previously appropriated by the legislature to conduct its own ibogaine research program after the state failed to find a qualifying drug-company partner. Texas Health and Human Services selected UTHealth Houston, with UTMB Galveston, to lead a statewide two-year trial studying ibogaine for addiction, traumatic brain injury and other behavioral health conditions. The commitment is the largest single state investment in psychedelic research to date.
U.S. Federal Government (policy). President Trump signed an executive order titled 'Accelerating Medical Treatments for Serious Mental Illness,' directing the FDA to prioritize review of psychedelic compounds and instructing the DEA and other agencies to ease research restrictions. The order named compounds such as psilocybin and ibogaine, allocated roughly $50 million toward federal-state research collaboration, and set the stage for expanded access pathways. Psychedelic equities rallied sharply the following trading day.
Compass Pathways plc (CMPS). Compass Pathways issued a statement welcoming the executive order, with CEO Kabir Nath framing it as recognition of the urgency of the mental health crisis and the potential of FDA-approved psychedelics. The company reiterated that it is running the largest classic-psychedelic trials to date and has posted two positive Phase 3 readouts for COMP360 in treatment-resistant depression. As the sector's most advanced developer, Compass is positioned to benefit directly from faster FDA review pathways.
Source: ir.compasspathways.com
Optimi Health Corp. (OPTHF). Optimi Health said it is extending its Health Canada-licensed GMP manufacturing platform to include ibogaine, having secured naturally derived supply from two sources in both hydrochloride and freebase form. The company plans 50 mg and 100 mg encapsulated dosage formats, positioning itself to support research after the executive order named ibogaine among prioritized compounds. The initiative broadens Optimi's psychedelic manufacturing beyond psilocybin and MDMA.
Incannex Healthcare Inc. (IXHL). Incannex said its PSX-001 oral synthetic psilocybin program for generalized anxiety disorder fits the executive order's priorities. The company cited completed Phase 2 results showing a 12.8-point HAM-A anxiety reduction versus 3.6 points for placebo, a 44% clinically meaningful response rate and a 27% remission rate sustained through 11 weeks, with no serious adverse events across 73 patients. Incannex said it holds over $70 million in cash, no debt and an active U.S. IND.
Helus Pharma (formerly Cybin) (HELP). Helus Pharma said it is collaborating with veterans-focused organization TARA Mind to support recruitment for the PARADIGM Phase 3 program evaluating HLP003 in major depressive disorder. The partnership aims to expand mental-health awareness and trial participation within the veteran community. It signals continued execution on the company's lead depression program despite the recent CEO transition.
U.S. Congress (federal policy). Reps. Michael McCaul (R-TX) and Morgan Luttrell (R-TX), joined by Lou Correa (D-CA) and Jack Bergman (R-MI), introduced the IBOGAINE Act to accelerate development of and access to psychedelic therapies for serious mental illness. The bill would direct the attorney general to decide within 60 days whether to move ibogaine from Schedule I to Schedule II and would require rescheduling proceedings for any Schedule I substance that completes Phase 3 trials. The legislation would enshrine President Trump's psychedelics executive order into federal law, a potential catalyst for the sector.
Oregon Health Authority (state policy). Oregon regulators proposed sharp increases to fees across the nation's first regulated psilocybin services program, including doubling annual manufacturer and service-center license fees from $10,000 to $20,000. The fee-funded program has seen revenue lag rising costs, and industry leaders warned the hikes could push more operators out of business and raise already-high treatment costs, with roughly half of licensed service centers already expired or surrendered. The proposal highlights the financial fragility of the state-regulated (non-FDA) access model.
U.S. FDA (regulatory). The FDA released final guidance on considerations for psychedelic clinical investigations, finalizing its 2023 draft and offering sponsors more flexibility on modeling abuse potential and measuring efficacy while addressing functional-unblinding challenges. The agency also scheduled a September 14, 2026 public hearing on the therapeutic use of psychedelics in supervised settings. Analysts characterized the receptive tone as reducing regulatory risk for developers such as Compass Pathways, AtaiBeckley, Cybin/Helus and GH Research.
Eli Lilly and Company / AtaiBeckley Inc. (LLY). Bloomberg reported that Eli Lilly was nearing an agreement to acquire psychedelic drugmaker AtaiBeckley, sending AtaiBeckley shares higher on the prospect of a Big Pharma entry into the sector. The report set up the following day's formal announcement. It signaled growing large-cap pharmaceutical conviction in psychedelic therapies for depression.
Capital Markets, M&A & Corporate
Financings, listings, and dealmaking tell you where conviction is flowing. This is how the sector's balance sheets and corporate structures shifted.
PharmAla Biotech Holdings Inc. (MDMA). PharmAla Biotech said the executive order's directive to establish access pathways for investigational psychedelics plays to its strengths, noting it already has GMP-grade LaNeo MDMA present in the U.S. and supplying programs including VA and Defense Health Agency channels. The company said it operates a commercial MDMA supply operation through its Australian joint venture and is advancing its next-generation ALA-002 candidate. PharmAla framed itself as a ready supplier as U.S. expanded-access demand potentially grows.
AtaiBeckley Inc. (ATAI). AtaiBeckley reported a first-quarter net loss of about $29.8 million and a loss of $0.08 per share, with roughly $954,000 in revenue, ahead of some analyst expectations. Cash, equivalents and short-term securities stood at $209.9 million as of March 31, which the company said funds operations into 2029. It reiterated that its BPL-003 (5-MeO-DMT) program is on track to begin a Phase 3 pivotal program in Q2 2026, with VLS-01 Phase 2 topline data expected in Q4 2026.
Compass Pathways plc (CMPS). Compass Pathways reported first-quarter 2026 results, posting a loss of roughly $0.30 per share and cash and equivalents of about $466 million against $50.5 million of debt as of March 31. Management reaffirmed that its cash position funds operations into 2028. The update followed the FDA's grant of rolling review and a National Priority Voucher for COMP360, keeping the company on track toward a Q4 2026 NDA submission.
GH Research PLC (GHRS). GH Research reported a first-quarter 2026 loss of about $0.31 per share and cash, equivalents and marketable securities of $267.3 million as of March 31. The company said it completed enrollment in its GH001-HV-106 clinical pharmacology trial and selected doses for its planned global Phase 3 pivotal program of inhaled mebufotenin (GH001) in treatment-resistant depression. GH Research said it is seeking FDA alignment while continuing to target Phase 3 initiation.
Optimi Health Corp. (OPTH). Optimi Health closed an oversubscribed US$15 million underwritten public offering tied to the uplisting of its common shares to the Nasdaq Capital Market, issuing 2.4 million shares at US$6.25 each. The shares began trading on Nasdaq under the ticker OPTH on May 20, 2026, with the offering closing on May 21. The uplisting and fresh capital strengthen the commercial-stage psilocybin manufacturer's access to U.S. investors as it scales exports to Australia and prepares clinical-trial supply.
GH Research PLC (GHRS). At the ASCP annual meeting (May 26-29 in Miami), GH Research presented three posters from its Phase 2b treatment-resistant depression trial of inhaled mebufotenin (GH001). The data showed rapid, clinically meaningful reductions in depression and anhedonia versus placebo at Day 8, with benefits maintained through a six-month open-label extension and efficacy appearing independent of the number of prior antidepressant failures. The presentations reinforce the profile of GH001 ahead of pivotal Phase 3 work.
Optimi Health Corp. (OPTH). Optimi Health completed a GMP production run of its 5mg psilocybin finished drug product, with output destined for commercial treatment-resistant depression prescriptions in Australia plus planned clinical trials in the U.S. and Europe. All stages, from biomass cultivation and API extraction to encapsulation and packaging, were done in-house under its Health Canada Drug Establishment Licence. The company also updated its bottling configuration for prescriber and patient ease of use, underscoring its vertically integrated manufacturing capacity.
Optimi Health Corp. (OPTH). Optimi Health shipped its first batch of naturally derived psilocybin, comprising biomass and finished 5mg capsules, from its Princeton, British Columbia facility to the United Kingdom to supply a planned Phase 2 clinical trial. The export moved under Health Canada export and UK Home Office import authorizations, and the capsules use the same formulation already prescribed in Australia. The shipment demonstrates Optimi's cross-border regulated supply capability, with the trial partner and indication to be disclosed later.
Silo Pharma, Inc. (SILO). Silo Pharma said Nasdaq confirmed that, as of June 17, 2026, it had regained compliance with the minimum closing bid price requirement under Listing Rule 5550(a)(2), removing a delisting risk. CEO Eric Weisblum said the company continues advancing its lead PTSD candidate SPC-15 toward a first-in-human trial. Regaining compliance stabilizes the micro-cap's listing status as it pursues its neuropsychiatric pipeline.
Clearmind Medicine Inc. (CMND). Clearmind Medicine was granted U.S. Patent No. 12,350,242, titled 'Binge Behavior Regulators,' covering compositions and methods using its proprietary molecule MEAI (5-methoxy-2-aminoindane) to regulate binge behaviors such as excessive drinking, eating, and gambling. The grant strengthens the intellectual property protecting Clearmind's lead platform, which is being studied for alcohol use disorder. Expanded IP is a value driver for the small-cap developer as it advances its clinical program.
Definium Therapeutics, Inc. (formerly MindMed) (DFTX). One day after its positive Emerge readout, Definium priced an upsized underwritten offering of 20,588,236 shares at $34.00 each for roughly $700 million in gross proceeds, up from an initially proposed $500 million. Underwriters received an option for an additional 3,088,235 shares. Proceeds are earmarked for R&D, commercialization preparation for DT120 ODT if approved, and general corporate purposes, substantially bolstering the balance sheet ahead of a potential regulatory filing.
Cybin Inc. (d/b/a Helus Pharma) (HELP). Cybin, now operating as Helus Pharma, said enrollment in its APPROACH Phase 3 trial of HLP003, a Breakthrough Therapy-designated deuterated psilocin analog for adjunctive major depressive disorder, had surpassed 86%, keeping topline data on track for Q4 2026. Alongside the update the company announced a US$50 million underwritten offering to fund the program and a second Phase 3 study, EMBRACE. The progress and financing advance one of the sector's most closely watched late-stage psilocybin-based programs.
AtaiBeckley Inc. (ATAI). AtaiBeckley was added to the Russell 2000 and Russell 3000 indexes in the FTSE Russell annual reconstitution effective June 29, 2026. Index inclusion typically brings passive-fund buying and broader institutional visibility. The addition marks a milestone for the merged psychedelic mental-health company as it advances Phase 3-bound programs including BPL-003.
Optimi Health Corp. (OPTH). Optimi Health completed another export of 5mg psilocybin capsules, about 1,000 capsules, to Australia for treatment-resistant depression patients, its third commercial shipment since launching the product in September 2025. The recurring shipments demonstrate steady demand and Optimi's ability to reliably supply the regulated Australian prescription market. The order flow supports the commercial-stage manufacturer's revenue base.
Eli Lilly and Company / AtaiBeckley Inc. (LLY). Eli Lilly and AtaiBeckley announced a definitive agreement for Lilly to acquire AtaiBeckley at $6.75 per share in cash, roughly $2.8 billion upfront and up to $3.8 billion including milestones, about a 40% premium to the recent VWAP. The lead asset is BPL-003 (mebufotenin benzoate), an intranasal synthetic 5-MeO-DMT for treatment-resistant depression heading into Phase 3. Expected to close in Q3 2026 subject to shareholder and regulatory approval, the deal marks a landmark Big Pharma acquisition in psychedelics and a validating exit for the sector.
What to Watch
The back half of 2026 turns on execution and integration. Compass targets a Q4 rolling-NDA completion with a potential 2027 launch; Definium and Helus Pharma both carry additional Phase 3 readouts into the second half; and the Eli Lilly–AtaiBeckley deal, expected to close in Q3, will test how a large-cap pharma operates a psychedelic pipeline. With the FDA's September public hearing on supervised psychedelic use ahead, the regulatory and commercial questions that once felt distant are now near-term and concrete.
This report is compiled by Psychedelic Invest from primary company disclosures and industry reporting; each story links its source. It is provided for informational purposes only and is not investment advice.